Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials

BACKGROUND: To determine how much an augmented analysis approach could improve the efficiency of prostate-specific antigen (PSA) response analyses in clinical practice. PSA response rates are commonly used outcome measures in metastatic castration-resistant prostate cancer (mCRPC) trial reports. PSA...

Descripción completa

Detalles Bibliográficos
Autores principales: Grayling, Michael J., McMenamin, Martina, Chandler, Robert, Heer, Rakesh, Wason, James M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793251/
https://www.ncbi.nlm.nih.gov/pubmed/35081926
http://dx.doi.org/10.1186/s12885-022-09227-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793251/
https://www.ncbi.nlm.nih.gov/pubmed/35081926
http://dx.doi.org/10.1186/s12885-022-09227-7

Ejemplares similares